<DOC>
	<DOC>NCT01017029</DOC>
	<brief_summary>The purpose of this study, in de novo heart transplant patients, is to evaluate whether delayed introduction of everolimus reduces the occurrence of wound healing problems, pericardial and/or pleural effusion and early acute renal insufficiency, as compared with immediate introduction of everolimus, in the firs six months after heart transplantation.</brief_summary>
	<brief_title>Everolimus in de Novo Heart Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criteria: Male or female cardiac transplant candidates 1865 years of age undergoing primary heart transplantation. Glomerular filtration rate (GFR by MDRD) â‰¥ 40 mL/min/1.73 m2 at randomization Exclusion criteria: Patients who are recipients of multiple solid organ transplants Patients who are HIVpositive or Hepatitis C positive (PCR only) or Bsurface antigen positive; Presence of Donor/Recipients serological mismatch for Hepatitis B or C; Recipients of organ from donors positive for Hepatitis Bsurface antigen; Panel Reactive Antibodies (cytotoxicity method) &gt; 30%. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>